European CHMP recommends license extension of dapagliflozin (Forxiga) for treatment of chronic kidney disease

The license extension is for the treatment of chronic kidney disease in adults.

SPS commentary:

NICE is due to appraise the clinical and cost effectiveness of dapagliflozin within its marketing authorisation for treating chronic kidney disease.

Source:

European Medicines Agency